Anuh Pharma Ltd
Anuh Pharma Ltd (ANUHPHR) last reported results for the quarter ended Jun 2026, with sales of ₹194 crore and net profit of ₹11 crore. The stock last traded at ₹82, a market capitalisation of ₹820 crore, on a P/E of 18.6. Over the past 52 weeks the stock has ranged between ₹66.7 and ₹99.5. Figures are as of 9 Oct 2026 and are not real time.
Anuh Pharma Ltd share price and key metrics
- Current price
- ₹82
- Market cap
- ₹820 cr
- Stock P/E
- 18.6
- Book value
- ₹35.1
- ROE
- 10.7%
- ROCE
- 14.9%
- Dividend yield
- 1.83%
- 52w high / low
- 99.5/66.7
Metrics as of 9 Oct 2026. Not real time.
Track Anuh Pharma Ltd
Cruxal reads every Anuh Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Anuh Pharma Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 12%
- 3 Years
- 14%
- TTM
- 10%
- 10 Years
- 4%
- 5 Years
- 10%
- 3 Years
- 3%
- TTM
- -4%
- 10 Years
- 3%
- 5 Years
- 8%
- 3 Years
- 8%
- 1 Year
- 0%
- 10 Years
- 13%
- 5 Years
- 14%
- 3 Years
- 14%
- Last Year
- 11%
Anuh Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹194 cr, up 4.3% from ₹186 cr a year earlier. Net profit was ₹11 cr, up 37.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 166 | 160 | 198 | 186 | 186 | 197 | 202 | 194 |
| Expenses | 149 | 145 | 179 | 176 | 174 | 178 | 182 | 178 |
| Operating profit | 17 | 15 | 19 | 10 | 12 | 19 | 20 | 16 |
| OPM % | 10% | 9% | 9% | 6% | 6% | 10% | 10% | 8% |
| Other income | 3 | 1 | 1 | 3 | 1 | 2 | -1 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 |
| Profit before tax | 18 | 13 | 17 | 11 | 10 | 18 | 16 | 17 |
| Tax % | 17% | 22% | 28% | 24% | 23% | 25% | 25% | 32% |
| Net profit | 15 | 10 | 12 | 8 | 8 | 13 | 12 | 11 |
| EPS (₹) | 1.50 | 1.03 | 1.24 | 0.83 | 0.76 | 1.34 | 1.17 | 1.14 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Anuh Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | 779 |
| Operating profit | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 62 | 67 |
| OPM % | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% | 9% |
| Net profit | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 | 44 |
| EPS (₹) | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.10 | 4.41 |
TTM is the trailing twelve months to the most recent quarter.
Anuh Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 |
| Borrowings | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 |
| Other liabilities | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 205 |
| Total liabilities | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
| Fixed assets | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 |
| CWIP | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 |
| Other assets | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 416 |
| Total assets | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 |
As reported by the company. Total assets equal total liabilities by construction.
Anuh Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 |
| Cash from investing | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 |
| Cash from financing | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 |
| Net cash flow | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -12 |
| Free cash flow | 25 | -5 | -22 | 13 | -25 | 27 | 52 | 8 | 17 | -11 |
| CFO / operating profit | 149% | 49% | 56% | 232% | -20% | 80% | 130% | 42% | 78% | 16% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Anuh Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% | 15% |
| Debtor days | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 | 113 |
| Inventory days | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 | 90 |
| Days payable | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 | 114 |
| Cash conversion cycle | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 | 89 |
| Working capital days | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 | 92 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Anuh Pharma Ltd shareholding pattern
Promoters held 71.79% at Jun 2026, up from 69.91% at Jun 2025. FIIs 0.01% and DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.91% | 69.91% | 69.91% | 69.91% | 71.81% | 71.81% | 71.79% | 71.79% |
| FIIs | 0.02% | 0.02% | 0.04% | 0.04% | 0.00% | 0.00% | 0.05% | 0.01% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 30.06% | 30.07% | 30.04% | 30.04% | 28.19% | 28.17% | 28.14% | 28.19% |
| No. of shareholders | 23,910 | 24,279 | 24,235 | 24,257 | 28,250 | 27,889 | 27,425 | 27,484 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Anuh Pharma Ltd corporate filings
- Intimation regarding the closure of Trading Window for dealing in Securities of the Company shall remain closed from Thursday, 01st October, 2026 till the expiry of 48 hours after the declaration ....Insider Trading / SASTlow impact
- Anuh Pharma Limited receives Income Tax demand order of 9.93 lakh for Assessment Year 2018-19Company Updatelow impact
Cruxal's analysis: Anuh Pharma Limited has disclosed the receipt of an Income Tax demand order under Section…
Read the full analysis - Anuh Pharma Ltd. Reports Strong Q1 FY27 Financials with 37.63% YoY PAT Growth and 15-20% Annual Growth GuidanceCompany Updatehigh impact
Cruxal's analysis: Anuh Pharma Ltd. delivered a robust performance for Q1 FY27, reporting an operating…
Read the full analysis - Anuh Pharma Ltd. Announces AGM Outcomes: Board Reappointments and Remuneration RevisionsCompany Updatelow impact
Cruxal's analysis: Anuh Pharma Ltd. has concluded its 66th Annual General Meeting, confirming the…
Read the full analysis - Anuh Pharma Ltd: General Disclosure under Regulation 30Company Updatelow impact
Cruxal's analysis: Anuh Pharma Ltd has filed a general disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Anuh Pharma Limited concludes 66th AGM; shareholders approve dividend of INR 1.50 per share and director re-appointmentsAGM/EGMlow impact
Cruxal's analysis: Anuh Pharma Limited has successfully concluded its 66th Annual General Meeting held on…
Read the full analysis - Anuh Pharma Ltd. Concludes 66th AGM; Declares Dividend of INR 1.50 per ShareAGM/EGMlow impact
Cruxal's analysis: Anuh Pharma Ltd. has successfully concluded its 66th Annual General Meeting held on 12th…
Read the full analysis - Anuh Pharma Ltd. Reports Q1 FY2027 Financial Results with Revenue of 193.81 Crore and Net Profit of 11.42 CroreCompany Updatehigh impact
Cruxal's analysis: Anuh Pharma Ltd. has released its unaudited financial results for the quarter ended June…
Read the full analysis - Anuh Pharma Ltd adopts revised policy for related party transactionsCompany Updatelow impact
Cruxal's analysis: Anuh Pharma Ltd has formally adopted a revised policy concerning Related Party…
Read the full analysis - Anuh Pharma Ltd withdraws application for reclassification of promoter shareholdingCompany Updatelow impact
Cruxal's analysis: Anuh Pharma Ltd has formally requested the withdrawal of its previously submitted…
Read the full analysis - Anuh Pharma reports Q1 FY27 results with 37.6% YoY PAT growth and improved EBITDA marginsResulthigh impact
Cruxal's analysis: Anuh Pharma Ltd. reported a strong performance for the quarter ended 30th June 2026, with…
Read the full analysis - Anuh Pharma Reports Q1 FY27 Results with 37.6% YoY Profit Growth; Promoters Withdraw Reclassification RequestBoard Meetinghigh impact
Cruxal's analysis: Anuh Pharma Limited reported a strong performance for the quarter ended 30th June 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.